Status:
COMPLETED
Haemodynamic Effects of GLP-1 and Glucagon in Healthy Male Volunteers
Lead Sponsor:
Cambridge University Hospitals NHS Foundation Trust
Conditions:
Cardiovascular Diseases
Eligibility:
MALE
18-40 years
Phase:
NA
Brief Summary
The study seeks to explore the cardiovascular effects of co-agonism at two peptide receptors, GLP-1 and glucagon. Glucagon, exenatide and 0.9% saline will be intravenously infused, both in isolation, ...
Detailed Description
Co-agonist peptides (such as at the GLP-1:glucagon receptor) are currently in clinical development for type 2 diabetes with the dual intention of reducing body weight and controlling blood glucose. Ho...
Eligibility Criteria
Inclusion
- Written informed consent to participate
- Aged 18 to 40
- Male
- Current non-smoker
- BMI \>18.0 and \<30kg/m2
Exclusion
- Female
- Sustained Hypertension (sustained BP \>160/100mmHg) or hypotension (systolic BP below 90 mmHg)
- Clinically significant heart disease
- Implanted heart pace-maker or implantable cardioverter defibrillator (ICD)
- Known active malignancy
- Known renal failure (creatinine \>140μmol/L)
- Known diabetes mellitus (type 1 or 2)
- Use of vasoactive medications or NSAIDS/aspirin within 24 hours of study visits
- Use of formal anticoagulant therapy such as, but not limited to, heparin, warfarin or rivaroxaban
- Current involvement in the active treatment phase of other research studies, (excluding observations/noninterventional)
- Any other clinical reason which may preclude entry in the opinion of the investigator
Key Trial Info
Start Date :
February 11 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2021
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT03835013
Start Date
February 11 2019
End Date
November 1 2021
Last Update
April 3 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Addenbrooke's Hospital
Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ